Dexamethasone in Hospitalized Patients with Covid-19

Cited by (1,035)

Items 401–500 of 1,035

1. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19
   Brian Thomas Garibaldi, Kunbo Wang, Matthew L. Robinson, Scott L. Zeger, Karen Bandeen‐Roche, Mei‐Cheng Wang, G. Caleb Alexander, Amita Gupta, Robert C. Bollinger, Yanxun Xu · 2021 · JAMA Network Open
2. Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study
   Elisa Estenssoro, Cecilia Loudet, Fernando G. Ríos, Vanina Siham Kanoore Edul, Gustavo Adrián Plotnikow, Macarena Andrian, Ignacio Romero, Damián Piezny, Marco Bezzi, Verónica Mandich et al. · 2021 · The Lancet Respiratory Medicine
3. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial
   Karim Ali, Tanweer Azher, Mahin Baqi, Alexandra Binnie, Sergio Borgia, François Martin Carrier, Yiorgos Alexandros Cavayas, Nicolas Chagnon, Matthew P. Cheng, John Conly et al. · 2022 · Canadian Medical Association Journal
4. COVID-19 and Acute Sarcopenia
   Carly Welch, Carolyn Anne Greig, Tahir Masud, Daisy V. Wilson, Thomas Jackson · 2020 · Aging and Disease
5. Influenza infection, SARS, MERS and COVID-19: Cytokine storm – The common denominator and the lessons to be learned
   Ryabkova, Varvara A., Churilov, Leonid P., Shoenfeld, Yehuda · 2021 · Clinical Immunology
6. Characterization of Bacterial and Fungal Infections in Hospitalized Patients With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections
   Christine J. Kubin, Thomas Howe McConville, Donald Dietz, Jason E Zucker, Michael S. May, Brian C. Nelson, Elizabeth Istorico, Logan Bartram, Jennifer L. Small-Saunders, Magdalena E. Sobieszczyk et al. · 2021 · Open Forum Infectious Diseases
7. Clinical Characteristics, Activity Levels and Mental Health Problems in Children with Long Coronavirus Disease: A Survey of 510 Children
   Danilo Buonsenso, Ferran Espuny Pujol, Daniel Munblit, Davide Pata, Sammie McFarland, Frances K Simpson · 2022 · Future Microbiology
8. Postintensive Care Syndrome in Survivors of Critical Illness Related to Coronavirus Disease 2019: Cohort Study From a New York City Critical Care Recovery Clinic*
   Miguel A. Martillo, Neha Subhash Dangayach, LAURA ROSENBAUM TABACOF, Lisa A. Spielman, Kristen Dams-O’Connor, Christy C. Chan, Roopa D. Kohli-Seth, Mar Cortes, Miguel Xavier Escalon · 2021 · Critical Care Medicine
9. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration
   Ruirong Chen, Zhien Lan, Jujian Ye, Limin Pang, Yi Liu, Wei Wu, Xiaohuan Qin, Yang Guo, Peidong Zhang · 2021 · Frontiers in Immunology
10. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis
    Paul E. Verweij, Roger J. M. Brüggemann, Élie Azoulay, Matteo Bassetti, Stijn I. Blot, Jochem B. Buil, Thierry Calandra, Tom M Chiller, Cornelius Joseph Clancy, Oliver A. Cornely et al. · 2021 · Intensive Care Medicine
11. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
    Evdoxia Kyriazopoulou, Thomas Huet, Giulio Cavalli, Andrea Gori, Miltiades Kyprianou, Peter Pickkers, Jesper Eugen‐Olsen, Mario Clerici, Francisco Veas, Gilles Châtellier et al. · 2021 · The Lancet Rheumatology
12. Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease
    Erin F. Balcom, Avindra Nath, Christopher Power · 2021 · Brain
13. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)
    Bita Shakoory, Ashley V. Geerlinks, Marta Wilejto, Kate F. Kernan, Melissa Hines, Micol Romano, David Piskin, Angelo Ravelli, Rashmi R. Sinha, Daniel Aletaha et al. · 2023 · Annals of the Rheumatic Diseases
14. Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention
    John P. Hussman · 2020 · Frontiers in Pharmacology
15. Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia
    Francesco Salton, Paola Confalonieri, Gianfranco Umberto Meduri, Pierachille Santus, Sergio Alfonso Harari, Raffaele Scala, Simone Lanini, Valentina Vertui, Tiberio Oggionni, Antonella Caminati et al. · 2020 · Open Forum Infectious Diseases
16. Antiviral and immunomodulatory activity of curcumin: A case for prophylactic therapy for COVID-19
    Rajesh Kumar Thimmulappa, Kiran Kumar Mudnakudu-Nagaraju, Chandan Shivamallu, Kuttinchantran Subramaniam, Arun Radhakrishnan, Suresh Bhojraj, Gowthamarajan Kuppusamy · 2021 · Heliyon
17. Clonal expansion and activation of tissue-resident memory-like T H 17 cells expressing GM-CSF in the lungs of patients with severe COVID-19
    Yu Zhao, Christoph Kilian, Jan‐Eric Turner, Lidia Bosurgi, Kevin Roedl, Patricia Bartsch, Ann-Christin Gnirck, Filippo Cortesi, Christoph Schultheiß, Malte Hellmig et al. · 2021 · Science Immunology
18. Pulmonary fibrosis secondary to COVID-19: a narrative review
    Suzana Érico Tanni, Alexandre Todorovic Fabro, André Luís Pereira de Albuquerque, Eloara V.M. Ferreira, Carlos Gustavo Yuji Verrastro, Márcio Valente Yamada Sawamura, Sérgio Marrone Ribeiro, Bruno Guedes Baldi · 2021 · Expert Review of Respiratory Medicine
19. The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
    C. Chakraborty, A. R. Sharma, M. Bhattacharya, G. Agoramoorthy, Sang-Soo Lee · 2021 · Frontiers in Pharmacology
20. COVID-19 therapeutics: Challenges and directions for the future
    Philip Cameron Robinson, David F. L. Liew, Helen L. Tanner, John R. Grainger, Raymond Allen Dwek, Ronald B. Reisler, Lawrence Steinman, Marc Feldmann, Ling‐Pei Ho, Tracy Hussell et al. · 2022 · Proceedings of the National Academy of Sciences
21. Therapeutic advances in COVID-19
    Naoka Murakami, Robert Hayden, Thomas E. Hills, Hanny T. Al-Samkari, Jonathan Dale Casey, Lorenzo Del Sorbo, Patrick R. Lawler, Meghan E. Sise, David E. Leaf · 2022 · Nature Reviews Nephrology
22. Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen
    Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geißlinger, Angela Corona et al. · 2021 · ACS Pharmacology & Translational Science
23. A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection
    Fiachra Humphries, Liraz Shmuel-Galia, Zhaozhao Jiang, Ruth Wilson, Philip Landis, Sze‐Ling Ng, Krishna Mohan Parsi, René Maehr, John Cruz, Ángel I. Morales-Ramos et al. · 2021 · Science Immunology
24. Drug repurposing for COVID-19: Approaches, challenges and promising candidates
    Yan-Ling Ng, Cyrill Kafi Salim, J. Chu · 2021 · Pharmacology and Therapeutics
25. Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study
    Waasila Jassat, Caroline Mudara, Lovelyn Ozougwu, Stefano Tempia, Lucille Hellen Blumberg, Mary‐Ann Davies, Yogan G. Pillay, Terence Carter, Ramphelane Morewane, Milani Wolmarans et al. · 2021 · The Lancet Global Health
26. Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19
    James P. Bridges, Eszter K. Vladar, Hua Huang, Robert J. Mason · 2021 · Thorax
27. Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19
    Amy Lee Lightner, Vikram Sengupta, Sascha Qian, John T. Ransom, Sam Suzuki, David J. Park, Timothy I. Melson, Brian P. Williams, James J. Walsh, Mustafa Awili · 2023 · CHEST Journal
28. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic
    Ali Ahmed Rabaan, Shamsah H. Al-Ahmed, Ranjit Sah, Ruchi Tiwari, Mohd. Iqbal Yatoo, Shailesh Kumar Patel, Mamta Pathak, Yashpal Singh Malik, Kuldeep Dhama, Karam Pal Singh et al. · 2020 · Annals of Clinical Microbiology and Antimicrobials
29. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses
    Marios Koutsakos, Louise C. Rowntree, Luca Hensen, Brendon Yew Loong Chua, Carolien E. van de Sandt, Jennifer R. Habel, Wuji Zhang, Xiaoxiao Jia, Łukasz Kedzierski, Thomas M. Ashhurst et al. · 2020 · Cell Reports Medicine
30. Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis
    Karimi, Amirali, Shobeiri, Parnian, Kulasinghe, Arutha, Rezaei, Nima · 2021 · Frontiers in Immunology
31. Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study
    Luca Saverio Belli, Constantino Fondevila, Paolo Angelo Cortesi, Sara Conti, Vincent Hassan Karam, René A. Adam, Audrey Coilly, Bo Goran Ericzon, Carmelo Loinaz, Valentín Cuervas‐Mons et al. · 2020 · Gastroenterology
32. Acute respiratory distress syndrome
    Katherine D. Wick, Lorraine B. Ware, Michael A. Matthay · 2024 · BMJ
33. The transmission modes and sources of COVID-19: A systematic review
    Heshu Sulaiman Rahman, Masrur S. Aziz, Ridha Hassan Hussein, Hemn Hassan Othman, Shirwan Hama Salih Omer, Eman Star Khalid, Nusayba Abdulrazaq Abdulrahman, Kawa Amin, Rasedee Abdullah · 2020 · International Journal of Surgery Open
34. Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection
    Pranesh Padmanabhan, Rajat Desikan, Narendra M. Dixit · 2020 · PLoS Computational Biology
35. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19
    Raman Kumar, Himani Rathi, Afrozul Haq, Sunil J. Wimalawansa, Alpana Sharma · 2020 · Virus Research
36. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
    Baranca Buijsers, Cansu Yanginlar, Marissa L. Maciej-Hulme, Quirijn de Mast, Johan van der Vlag · 2020 · EBioMedicine
37. Retinal vein occlusion in COVID-19: A novel entity
    Jay Umed Sheth, Raja Narayanan, Jay Goyal, Vinod Goyal · 2020 · Indian Journal of Ophthalmology
38. Pathogenesis of Respiratory Viral and Fungal Coinfections
    Fabián Salazar, Elaine Bignell, Gordon D. Brown, Peter C. Cook, Adilia Warris · 2021 · Clinical Microbiology Reviews
39. Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study‘
    Maria De Santis, Antonio Voza, Victor Savevski, Salvatore Badalamenti, Maurizio Cecconi, Alberto Mantovani, Carlo Francesco Selmi · 2021 · Annals of the Rheumatic Diseases
40. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine
    Aaron Z Reyes, Kelly A. Hu, Jacob Teperman, Theresa Wampler Muskardin, Jean‐Claude Tardif, Binita Shah, Michael H. Pillinger · 2020 · Annals of the Rheumatic Diseases
41. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab
    Alessandro Rambaldi, Giuseppe Gritti, Maria Caterina Micò, Marco Frigeni, Gianmaria Borleri, Anna Salvi, Francesco Landi, Chiara Pavoni, Aurelio Sonzogni, Andrea Gianatti et al. · 2020 · Immunobiology
42. Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection
    Jennifer Chen, Mia Madel Alfajaro, Ryan Dz-Wei Chow, Jin Wei, Renata B. Filler, Stephanie C. Eisenbarth, Craig B. Wilen · 2021 · Journal of Virology
43. Co-infection in critically ill patients with COVID-19: an observational cohort study from England
    Vadsala Baskaran, Hannah Lawrence, Louise Lansbury, Karmel Webb, Shahideh Safavi, Nurul I Zainudin, Tausif Huq, Charlotte Eggleston, Jayne P. Ellis, Clare E Thakker et al. · 2021 · Journal of Medical Microbiology
44. Bacterial infections and patterns of antibiotic use in patients with COVID‐19
    Alvaro Goncalves Mendes Neto, Kevin Bryan Lo, Ammaar Wattoo, Grace Salacup, Jerald Pelayo, Robert DeJoy, Ruchika Bhargav, Fahad Gul, Eric L. Peterson, Jeri Albano et al. · 2020 · Journal of Medical Virology
45. Natural history of COVID-19 and therapeutic options
    Philippe Gautret, Matthieu Million, Pierre‐André Jarrot, Laurence Camoin‐Jau, Philippe Colson, Florence Fenollar, Marc Léone, Bernard La Scola, Christian Albert Devaux, Jean Yves Gaubert et al. · 2020 · Expert Review of Clinical Immunology
46. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report
    Amirreza Veisi, Abbas Bagheri, M Eshaghi, Mohamad Hasan Rikhtehgar, Mozhgan Rezaei Kanavi, Reza Farjad · 2021 · European Journal of Ophthalmology
47. COVID-19-associated opportunistic infections: a snapshot on the current reports
    Amir Abdoli, Shahab Falahi, Azra Kenarkoohi · 2021 · Clinical and Experimental Medicine
48. Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)
    Edina Cenko, Lina Badimón, Raffaele Bugiardini, Marc J. Claeys, Giuseppe De Luca, Cor de Wit, Geneviève Dérumeaux, Maria Dorobanţu, Dirk Jan Duncker, Etto C. Eringa et al. · 2021 · Cardiovascular Research
49. COVID-19 and antimicrobial resistance: A cross-study
    Sidra Ghazali Rizvi, Shaikh Ziauddin Ahammad · 2021 · The Science of The Total Environment
50. Deciphering the state of immune silence in fatal COVID-19 patients
    Pierre Bost, Francesco De Sanctis, Stefania Canè, Stefano Ugel, Katia Donadello, Monica Castellucci, Eyal David, Alessandra Fiore, Cristina Anselmi, Roza Maria Barouni et al. · 2021 · Nature Communications
51. Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
    Daniele Focosi, Fabrizio Maggi · 2021 · Reviews in Medical Virology
52. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
    Johannes Korth, Michael Jahn, Oliver Dorsch, Olympia Evdoxia Anastasiou, Burkhard Sorge-Hädicke, Ute Eisenberger, Anja Gäckler, Ulf Dittmer, Oliver Witzke, Benjamin Wilde et al. · 2021 · Viruses
53. COVID-19 and Multisystem Inflammatory Syndrome in Latin American Children
    Omar Yassef Antúnez‐Montes, Maria Isabel Escamilla, Augusto Flavio Figueroa-Uribe, Erick Arteaga‐Menchaca, Manuel Lavariega-Saráchaga, Perla Salcedo‐Lozada, Priscilla Melchior, Rodrigo Beréa de Oliveira, Juan Carlos Tirado Caballero, Hernando Pinzón-Redondo et al. · 2020 · The Pediatric Infectious Disease Journal
54. In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation
    Antonio Olivas‐Martínez, José Luis Cárdenas-Fragoso, José Víctor Jiménez, Oscar Arturo Lozano-Cruz, Edgar Ortíz‐Brizuela, Víctor Hugo Tovar-Méndez, Carla Medrano-Borromeo, Alejandra Martínez-Valenzuela, Carla Marina Román-Montes, Bernardo Alfonso Martínez-Guerra et al. · 2021 · PLoS ONE
55. The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation
    Piotr Rzymski, Leszek Borkowski, Marcin Drąg, Robert Flisiak, Jacek Jemielity, Jacek Krajewski, Agnieszka Mastalerz–Migas, Andrzej Matyja, Krzysztof Pyrć, Krzysztof Adam Simon et al. · 2021 · Vaccines
56. COVID ‐19: immunopathology, pathophysiological mechanisms, and treatment options
    Larissa E. van Eijk, Mathijs Binkhorst, Arno R. Bourgonje, Annette K. Offringa, Douwe Johannes Mulder, Eelke Marijn Bos, Nikola Kolundžić, Amaal Eman Abdulle, Peter H. J. van der Voort, Marcel G. M. Olde Rikkert et al. · 2021 · The Journal of Pathology
57. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review
    Khai Li Chai, Sarah J Valk, Vanessa Piechotta, Catherine Kimber, Ina Monsef, Carolyn J. Doree, Erica M. Wood, Abigail Lamikanra, David J. Roberts, Zoe McQuilten et al. · 2020 · Cochrane Database of Systematic Reviews
58. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida
    Eduardo Oliveira, Amay Parikh, ARNALDO FABIAN LOPEZ‐RUIZ, Maria Carrilo, Joshua Goldberg, Martin Cearras, Khaled Fernainy, Sonja Andersen, Luis Mercado, Jian Guan et al. · 2021 · PLoS ONE
59. Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19
    Keller, Marla J, Kitsis, Elizabeth A, Arora, Shitij, Chen, Jen-Ting, Agarwal, Shivani, Ross, Michael J, Tomer, Yaron, Southern, William · 2020 · Journal of Hospital Medicine
60. Challenges for Drug Repurposing in the COVID-19 Pandemic Era
    Janet Sultana, Salvatore Crisafulli, Flic Gabbay, Elizabeth Lynn, Saad Shakir, Gianluca Trifirò · 2020 · Frontiers in Pharmacology
61. Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19
    Ankeet S. Bhatt, Karola Jering, Muthiah Vaduganathan, Brian Lee Claggett, Jonathan W. Cunningham, Ning An Rosenthal, James Signorovitch, Jens Jakob Thune, Orly Vardeny, Scott David Solomon · 2020 · JACC Heart Failure
62. Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup
    Eric J. Rubin, Dan L. Longo, Lindsey Robert Baden · 2021 · New England Journal of Medicine
63. Acute respiratory distress syndrome heterogeneity and the septic ARDS subgroup
    Huikang Xu, Shiying Sheng, Weiwei Luo, Xiao-Fang Xu, Zhaocai Zhang · 2023 · Frontiers in Immunology
64. Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
    Kyle Rosenke, Frederick Hansen, Benjamin H. Schwarz, Friederike Feldmann, Elaine Haddock, Rebecca Rosenke, Kent Barbian, Kimberly D. Meade-White, Atsushi Okumura, Shanna S. Leventhal et al. · 2021 · Nature Communications
65. COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment
    Khalil El Karoui, An S. De Vriese · 2022 · Kidney International
66. SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation
    Kiandokht Keyhanian, Raffaella Pizzolato Umeton, Babak Mohit, Vahid Davoudi, Fatemeh Hajighasemi, Mehdi Ghasemi · 2020 · Journal of Neuroimmunology
67. COVID-19: Pulmonary and Extra Pulmonary Manifestations
    Islam Hussam Elrobaa, Karl James New · 2021 · Frontiers in Public Health
68. Molnupiravir and Its Antiviral Activity Against COVID-19
    Lili Tian, Zehan Pang, Maochen Li, Fuxing Lou, Xiaoping An, Shaozhou Zhu, Lihua Song, Yigang Tong, Huahao Fan, Junfen Fan · 2022 · Frontiers in Immunology
69. Nanotechnology-based strategies against SARS-CoV-2 variants
    Xiangang Huang, Edo Kon, Xuexiang Han, Xingcai Zhang, Na Kong, Michael J. Mitchell, Dan Peer, Wei Tao · 2022 · Nature Nanotechnology
70. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
    RECOVERY Collaborative Group, Peter Horby, Marion M. Mafham, Leon Peto, Mark Robin Campbell, Guilherme Pessoa-Amorim, Enti Spata, Natalie Staplin, Jonathan Emberson, Benjamin Prudon et al. · 2021 · medRxiv
71. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
    Jozefien Declercq, Karel F. A. Van Damme, Elisabeth De Leeuw, Bastiaan Maes, Cédric Bosteels, Simon Jan Tavernier, Stefanie L. De Buyser, Roos Colman, Maya Hites, Gil Verschelden et al. · 2021 · The Lancet Respiratory Medicine
72. Increased odds of death for patients with interstitial lung disease and covid-19: a case-control study
    Esposito, Anthony J., Menon, Aravind A., Ghosh, Auyon J., Putman, Rachel K., Fredenburgh, Laura E., El-Chemaly, Souheil Y., Goldberg, Hilary J., Baron, Rebecca M., Hunninghake, Gary M., Doyle, Tracy J. · 2020 · American Journal of Respiratory and Critical Care Medicine
73. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines
    Janet Sultana, Paola Maria Cutroneo, Salvatore Crisafulli, Gabriele Puglisi, Gaetano Caramori, Gianluca Trifirò · 2020 · Drug Safety
74. Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS
    Gianfranco Umberto Meduri, Djillali Annane, Marco Confalonieri, George Panagiotis Chrousos, Bram N. Rochwerg, Amanda D. Busby, Barbara Ruaro, Bernd Meibohm · 2020 · Intensive Care Medicine
75. A distinct innate immune signature marks progression from mild to severe COVID-19
    Stéphane Chevrier, Yves Zurbuchen, Carlo Cervia, Sarah Adamo, Miro E. Raeber, Natalie de Souza, Sujana Sivapatham, Andrea Jacobs, Esther Bächli, Alain Rudiger et al. · 2020 · Cell Reports Medicine
76. Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease
    Keyvan Razazi, Romain Arrestier, Anne-Fleur Haudebourg, Brice Benelli, Guillaume Carteaux, Jean‐Winoc Decousser, Slim Fourati, Paul‐Louis Woerther, Frédéric Schlemmer, Anaïs Charles‐Nelson et al. · 2020 · Critical Care
77. The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections
    Ren‐Jun Hsu, Wei-Chieh Yu, Guan-Ru Peng, Chih-Hung Ye, SuiYun Hu, Patrick Chun Theng Chong, Kah Yi Yap, Jamie Yu Chieh Lee, Weichen Lin, Shu‐Han Yu · 2022 · Frontiers in Immunology
78. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
    Francesco Perrone, Maria Carmela Piccirillo, Paolo A. Ascierto, Carlo Salvarani, Roberto Parrella, Anna Maria Marata, Patrizia Popoli, Laurenzia Ferraris, Massimiliano Maria Marrocco-Trischitta, Diego Ripamonti et al. · 2020 · Journal of Translational Medicine
79. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions
    Malina A. Bakowski, Nathan Beutler, Karen C. Wolff, Melanie G. Kirkpatrick, Emily Chen, Tu-Trinh Nguyen, Laura Riva, Namir Shaabani, Mara Parren, James Ricketts et al. · 2021 · Nature Communications
80. IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
    Kishimoto, Tadamitsu, Kang, Sujin · 2022 · Annual Review of Immunology
81. COVID-19 in patients with hematologic malignancy
    Petra Langerbeins, Michael J. Hallek · 2022 · Blood
82. Musculoskeletal involvement of COVID-19: review of imaging
    Santhoshini Leela Ramani, Jonathan D. Samet, Colin K. Franz, Christine Hsieh, Cuong V. Nguyen, Craig Horbinski, Swati D. Deshmukh · 2021 · Skeletal Radiology
83. Clinical Olfactory Working Group consensus statement on the treatment of postinfectious olfactory dysfunction
    Alfred Bentsi Addison, Billy L. K. Wong, Tanzime Ahmed, Alberto Macchi, Iordanis Konstantinidis, Caroline Huart, Johannes Frasnelli, Alexander Wieck Fjældstad, Vijay R. Ramakrishnan, Philippe Rombaux et al. · 2021 · Journal of Allergy and Clinical Immunology
84. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies
    Baik, Alan H., Oluwole, Olalekan O., Johnson, Douglas B., Shah, Nina, Salem, Joe-Elie, Tsai, Katy K., Moslehi, Javid J. · 2021 · Circulation Research
85. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19
    Nils Kappelmann, Robert Dantzer, Golam Mohammed Khandaker · 2021 · Psychoneuroendocrinology
86. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative
    Kathleen M Andersen, Benjamin A Bates, Emaan Rashidi, Amy L Olex, Roslyn Bernstein Mannon, Rena C Patel, Jasvinder Singh, Jing Sun, Paul G Auwaerter, Derek K Ng et al. · 2021 · The Lancet Rheumatology
87. High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory Failure
    Lila Bouadma, Armand Mekontso Dessap, Charles Burdet, Hamid Merdji, Julien Poissy, Claire Dupuis, Christophe Guitton, Carole Schwebel, Yves Cohen, Cédric Bruel et al. · 2022 · JAMA Internal Medicine
88. C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19
    Milad Sharifpour, Srikant Rangaraju, Michael Liu, Darwish Alabyad, Fadi B. Nahab, Christina Creel-Bulos, Craig S. Jabaley · 2020 · PLoS ONE
89. Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety
    Peter Breining, Anne Lier Frølund, Jesper Falkesgaard Højen, Jesper Damsgaard Gunst, Nina Breinholt Stærke, Eva Aggerholm Sædder, Manuel Cases, Paul S Little, Lars Peter Nielsen, Ole Schmeltz Søgaard et al. · 2020 · Basic & Clinical Pharmacology & Toxicology
90. Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England
    Edward Knock, Lilith K. Whittles, John A. Lees, Pablo N. Perez‐Guzman, Robert Verity, Richard G. FitzJohn, Katy A. M. Gaythorpe, Natsuko Imai, Wes R. Hinsley, Lucy Okell et al. · 2021 · Science Translational Medicine
91. Calming the cytokine storm in COVID-19
    Randy Quentin Cron, Roberto Caricchio, Winn W Chatham · 2021 · Nature Medicine
92. Two Years into the COVID-19 Pandemic: Lessons Learned
    Severino Jefferson Ribeiro da Silva, Jéssica Catarine Frutuoso do Nascimento, Renata Pessôa Germano Mendes, Klarissa Miranda Guarines, Caroline Targino Alves da Silva, Poliana Gomes da Silva, Jurandy Júnior Ferraz de Magalhães, Justin R. J. Vigar, Abelardo Silva‐Júnior, Alain Kohl et al. · 2022 · ACS Infectious Diseases
93. Impact of COVID-19 in solid organ transplant recipients
    Lara A. Danziger‐Isakov, Emily A. Blumberg, Oriol Manuel, Martina Sester · 2020 · American Journal of Transplantation
94. Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial
    Xiao Tang, Yingmei Feng, Ji-Xiang Ni, Jia-Ying Zhang, Li-Min Liu, Ke Hu, Xiu‐Zhi Wu, Ji-Xian Zhang, Jun-Wen Chen, Jian-Chu Zhang et al. · 2021 · Respiration
95. COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm
    Wonhwa Lee, June Hong Ahn, Hee Ho Park, Hong Nam Kim, Hyelim Kim, Youngbum Yoo, Hyosoo Shin, Kyung Soo Hong, Jong Geol Jang, Chun Gwon Park et al. · 2020 · Signal Transduction and Targeted Therapy
96. Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave?
    Damien Contou, Megan Fraissé, Olivier Pajot, Jo-Anna Tirolien, Hervé Mentec, Gaëtan Plantefève · 2021 · Critical Care
97. SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress
    Ryan P. Chang, Abrar Mamun, Abishai Dominic, Nhat‐Tu Le · 2021 · Frontiers in Physiology
98. Cost‐effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa
    Susan Cleary, Thomas Wilkinson, Cynthia Raissa Tchuem Tamandjou, Sumaiyah Docrat, Geetesh C. Solanki · 2021 · BMC Health Services Research
99. The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection
    Lisa Henß, Arne Auste, Christoph Schürmann, Christin Schmidt, Christine von Rhein, Michael D. Mühlebach, Barbara S. Schnierle · 2021 · Journal of General Virology
100. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19
     Gilmar Reis, Eduardo Augusto dos Santos Moreira Silva, Daniela Carla Medeiros Silva, Lehana Thabane, Gurmit Singh, Jay Park, Jamie I. Forrest, Ofir Harari, Castilho Vitor Quirino dos Santos, Ana Paula Figueiredo Guimaraes Almeida et al. · 2021 · JAMA Network Open